BRÈVE

sur Renalogic

Dialysis Patient Experience Report Highlights Unpredictable Impact of Treatment

CHICAGO, IL / ACCESSWIRE / July 10, 2024 / Renalogic, a healthcare solutions provider for chronic kidney disease (CKD), collaborated with Lyfebulb to survey dialysis patients, revealing significant challenges in managing the illness. The survey showed that 62% of dialysis treatments were unplanned, underscoring the unpredictability of CKD. More than half of the patients had to stop working, and 50% visited the emergency room or were hospitalized in the past year.

Kevin Weinstein, CEO of Renalogic, emphasized the survey's aim to drive changes that improve dialysis experiences and clinical outcomes. The report covers various topics, such as the financial impact, physical and mental strain, access to high-quality care, and workplace effects.

Karin Hehenberger, President of Lyfebulb, highlighted the life-saving nature of dialysis while acknowledging the need for better solutions for those living with end-stage renal disease (ESRD). Both organizations are committed to using these insights to enhance the quality of life for dialysis patients.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Renalogic